Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced that its Chief Executive Officer, Mark Velleca, M.D., Ph.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference taking place June 4-6, 2024, in New York, NY.
2024年5月29日，馬薩諸塞州劍橋市（全球新聞社）-- Black Diamond Therapeutics, Inc. （納斯達克：BDTX）是一家臨床階段的腫瘤學公司，正在開發針對患有癌症的致癌突變家族的MasterKey療法，今天宣佈，其首席執行官馬克·韋勒卡博士將於2024年6月4-6日在紐約參加Jefferies全球醫療保健會議的爐邊聊天。
Presentation details are as follows:
陳述細節如下：
- 7:30-7:55am ET on Wednesday, June 5
- 6月5日（星期三）美國東部時間7:30-7:55am
A live webcast of the event can be accessed by visiting the investors relations section of the Company's website, www.blackdiamondtherapeutics.com. A replay of the webcast will also be available and archived for 90 days following the event.
可通過訪問公司網站的投資人關係部分，www.blackdiamondtherapeutics.com，進入活動的現場互聯網廣播。互聯網廣播的回放也將可用並將存檔90天。
About Black Diamond Therapeutics
Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company's MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat CNS disease. The Company is advancing two clinical-stage programs: BDTX-1535, a brain-penetrant fourth-generation EGFR MasterKey inhibitor targeting EGFR mutant NSCLC and GBM, and BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS and BRAF alterations in solid tumors. For more information, please visit www.blackdiamondtherapeutics.com.
關於黑鑽石治療
黑鑽石治療是一家臨床階段的腫瘤學公司，正在開發針對患有癌症的致癌突變家族的MasterKey療法。公司的MasterKey療法旨在治療廣泛的遺傳定義腫瘤，克服耐藥性，最小化野生型介導的毒性，並能夠穿透血腦屏障以治療中樞神經系統疾病。該公司正在推進兩個臨床階段計劃：BDTX-1535，一種穿透血腦屏障的第四代EGFR MasterKey抑制劑，針對EGFR突變型NSCLC和GBM，以及BDTX-4933，一種穿透血腦屏障的RAF MasterKey抑制劑，針對固體腫瘤中KRAS、NRAS和BRAF改變。有關更多信息，請訪問www.blackdiamondtherapeutics.com.
Contacts
For Investors:
Mario Corso, Head of Investor Relations, Black Diamond Therapeutics
mcorso@bdtx.com
聯繫方式
對於投資者：
黑鑽石治療投資者關係負責人馬里奧·科索（Mario Corso）
mcorso@bdtx.com
For Media:
media@bdtx.com
對於媒體人員：
media@bdtx.com
譯文內容由第三人軟體翻譯。